--- title: "Cognition Therapeutics (CGTX) stock and investor profile" url: "https://aibio.space/companies/cognition-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Cognition Therapeutics, Inc. (NASDAQ: CGTX), United States. The directory classifies it as Biotechnology." --- CGTX Cognition Therapeutics, Inc. NASDAQ · United States # Cognition Therapeutics (CGTX) news Listings · 2025-08-26 ## [Cognition Therapeutics regains compliance with Nasdaq $1.00 bid price rule](https://aibio.space/news/cognition-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/) Nasdaq told Cognition Therapeutics on August 26, 2025 that the company again meets its listing requirements after the stock closed above $1.00 for more than ten trading days. ## Latest Cognition Therapeutics news We have not published a story on Cognition Therapeutics yet. When there is news, it will appear here. ## Cognition Therapeutics at a glance - **Ticker**: CGTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $34.0 million ### Related companies - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) NASDAQ: CBIO - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) OTC: VINC - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO - [Precigen](https://aibio.space/companies/precigen/) NASDAQ: PGEN - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) NASDAQ: CVKD - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) NASDAQ: VERA ### Also on NASDAQ - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) RLMD - [BioCardia](https://aibio.space/companies/biocardia/) BCDA - [LENSAR](https://aibio.space/companies/lensar/) LNSR - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) TELO - [Insight Molecular Diagnostics](https://aibio.space/companies/insight-molecular-diagnostics/) IMDX - [MoonLake Immunotherapeutics](https://aibio.space/companies/moonlake-immunotherapeutics/) MLTX ## What Cognition Therapeutics does Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, zervimesine, also known as CT1812, is an orally delivered small molecule designed to prevent oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein, from binding to neurons. The company's initial focus was Alzheimer's disease. Its Phase 2 COG0201 (SHINE) study reported top-line results in 2024. The Phase 2 COG0203 (START) study in mild cognitive impairment and early-stage Alzheimer's disease completed enrollment in December 2025, with top-line results expected after all participants complete 18 months of treatment. The company plans to develop zervimesine for dementia with Lewy bodies psychosis, following the Phase 2 COG1201 (SHIMMER) study in 130 adults with mild-to-moderate DLB. It holds an end-of-Phase 2 meeting with the FDA for a Phase 3 program in Alzheimer's disease, and it reports Fast Track designation from the FDA for Alzheimer's disease. Its clinical trials have been funded primarily by grants from the National Institute on Aging, and it retains worldwide rights to zervimesine for all indications. | Product or program | What it is | Stage | |---|---|---| | Zervimesine (CT1812) for Alzheimer's disease | Oral small molecule that protects neuronal synapses from pathogenic protein oligomers | Phase 2 (START); Phase 3 program planned | | Zervimesine for DLB psychosis | Planned development program for psychosis in dementia with Lewy bodies | Planned | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/cgtx-20251231x10k.htm). ## Cognition Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$37.2 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | [$41.7 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | | Net income (loss) | [-$23.5 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | [-$34.0 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | | Cash from operations | [-$24.6 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | [-$28.5 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | | Cash and equivalents | [$36.8 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926092362/) | [$25.0 million](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034880/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $34.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cognition Therapeutics What is the ticker symbol of Cognition Therapeutics? Cognition Therapeutics, Inc. trades under the ticker CGTX on NASDAQ. Where is Cognition Therapeutics listed? Cognition Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Cognition Therapeutics? The SEC Central Index Key (CIK) for Cognition Therapeutics, Inc. is 1455365. Its filings are on SEC EDGAR. How many shares does Cognition Therapeutics have outstanding? 95,093,746 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Cognition Therapeutics listed under? Our directory records Cognition Therapeutics, Inc. under United States. What does Cognition Therapeutics do? Our directory classifies Cognition Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Cognition Therapeutics? The ISIN recorded for Cognition Therapeutics, Inc. is US19243B1026. Does aibio.space cover Cognition Therapeutics? aibio.space lists Cognition Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cognition Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Cognition Therapeutics develop? Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, zervimesine, also known as CT1812, is an orally delivered small molecule designed to prevent oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein, from binding to neurons. What is Zervimesine (CT1812) for Alzheimer's disease from Cognition Therapeutics? Zervimesine (CT1812) for Alzheimer's disease: Oral small molecule that protects neuronal synapses from pathogenic protein oligomers Stage: Phase 2 (START); Phase 3 program planned. What is Zervimesine for DLB psychosis from Cognition Therapeutics? Zervimesine for DLB psychosis: Planned development program for psychosis in dementia with Lewy bodies Stage: Planned. Is Cognition Therapeutics profitable? Cognition Therapeutics, Inc. reported a net loss of $23.5 million for the fiscal year ended Dec 31, 2025, and used $24.6 million of cash in operations, per its annual report to the SEC. How much does Cognition Therapeutics spend on research and development? $37.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Cognition Therapeutics have? $34.0 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Cognition Therapeutics Members talk about Cognition Therapeutics (CGTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cognition Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-12-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1455365/000110465925122555/tm2533712d1_8k.htm) 2. 2025-08-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1455365/000110465925084835/tm2524576-1_424b5.htm) 3. 2025-08-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1455365/000110465925083059/tm2524388d1_8k.htm) 4. 2025-03-20 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1455365/000110465925026129/tm259710d1_424b5.htm) 5. 2025-03-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1455365/000110465925022969/tm258979d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CGTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-CGTX/). ## SEC filings and registration - **SEC name**: Cognition Therapeutics Inc - **CIK**: 1455365 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CGTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2500 WESTCHESTER AVE, PURCHASE, NY, 10577 - **Phone**: 412-481-2210 - **Shares outstanding**: 95,093,746 as of 2026-08-04 (10-Q filed 2026-08-07) - **Former names**: COGNITION THERAPUTICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1455365/000110465926117948/tm2628101d1_8k.htm) filed 2026-10-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1455365/000110465926092362/cgtx-20260630x10q.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/tm2622462d1_8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1455365/000110465926077060/tm2618699d1_8k.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1455365/000110465926075442/tm2618236d1_8k.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1455365/000110465926070345/tm2616896d1_8k.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/tm2615260d1_8k.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1455365/000110465926057545/cgtx-20260331x10q.htm) filed 2026-05-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001455365), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cognition Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CGTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cognition Therapeutics, Inc. - **Ticker**: CGTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US19243B1026 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CGTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cognition-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cognition Therapeutics (CGTX) stock and investor profile", 2026-10-31, https://aibio.space/companies/cognition-therapeutics/